Background: To determine genomic alterations in head and neck squamous cell carcinoma (HNSCC) using formalinfixed, paraffin-embedded (FFPE) tumors obtained through routine clinical practice, selected cancer-related genes were evaluated and compared with alterations seen in frozen tumors obtained through research studies.
introduction
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease arising from the mucosal lining of the upper aerodigestive tract including the nasal cavity, paranasal sinuses, oral cavity, pharynx, and larynx. Common causes of HNSCC are tobacco and alcohol use [1] . High-risk human papillomavirus (HPV) is an established cause of HNSCC arising primarily in the oropharynx [2] . Recent data suggest that a subset of nasal cavity and paranasal sinus HNSCCs is also associated with HPV [3] . Clinically, patients with HPV-positive HNSCC, especially nonsmokers, have significantly better prognosis compared with patients with HPV-negative HNSCC after treatments for newly diagnosed as well as recurrent/metastatic diseases [4] [5] [6] [7] .
To improve understanding of the underlying cancer biology and leverage the findings to optimize the HNSCC management, there have been concerted efforts to genomically characterize HNSCC. To date, four large studies have reported the genomic alterations in HNSCC; three studies evaluated the genomic alterations using whole exome sequencing (WES) and whole genome sequencing (WGS) [8] [9] [10] , and one study applied a targeted approach of evaluating 617 selected cancer-associated genes [11] . However, these earlier studies were conducted using frozen primary tumors, which are not common tissue collection or storage method in clinical practice. In this study, we evaluated genomic alterations of HNSCC using formalin-fixed, paraffinembedded (FFPE) tumors obtained through routine clinical practice and compared with publically available sequencing data generated from frozen tumors. In addition, we have evaluated carcinomas arising in the sinonasal tract where ∼20% of the tumors are high-risk HPV positive [3] and established similarities in their HPV-specific profiles compared with HPV-positive oropharynx SCC. materials and methods patient characteristics and next-generation sequencing-based genomic profiling assay DNA extracted from FFPE tissue samples for 252 HNSCC patients was analyzed by Clinical Laboratory Improvement Amendments (CLIA)-certified, next-generation sequencing (NGS)-based assay, ordered by clinicians as a routine clinical practice, designated as the Foundation Medicine (FM) cohort (FoundationOne, Foundation Medicine, Cambridge, MA). Methods for the NGS-based clinical cancer gene assay used in this project have been previously published and assay performance has been rigorously validated [12] . We also provide a summary of the sequencing methods in supplementary File, available at Annals of Oncology online. The version of the FoundationOne assay used in this study was in use between December 2012 and August 2014 and evaluated exons of 236 cancer-related genes and introns of 19 genes frequently re-arranged in cancer (supplementary Table S1 , available at Annals of Oncology online).
Copy number and mutation data from 279 HNSCC samples (TCGA cohort) with known HPV status were downloaded from cBioPortal (http:// www.cbioportal.org/public-portal/); TCGA copy number data were GISTIC transformed before analysis [10, 13] . The genomic information of 236 genes contained in the FoundationOne assay was extracted. Similarly, the genomic information of overlapping 122 genes contained in the FoundationOne assay was extracted from the University of Chicago dataset (Chicago cohort) [11] . The genomic features selected from TCGA and Chicago data were tabulated with the genomic profiles from the FoundationOne assay. Because generearrangement data were not available in the Chicago cohort [11] , we considered only short variants and copy number alterations in 236 cancerrelated genes.
determination of the HPV tumor status by sequencing, immunohistochemistry, in situ hybridization and the multivariate organization of combinatorial alterations algorithm in HNSCC
To assess viral content of specimens, sequencing reads are aligned to a multitude of clinically relevant viral genomes, including all common isoforms of HPV as previously published [14] . Immunohistochemistry was carried out to determine p16 expression using a p16 mouse monoclonal antibody ( predilute, mtm-CINtech, E6H4) and high-risk HPV status was determined by in situ hybridization (ISH) using a cocktail probe (GenPoint HPV Probe Cocktail, Dako) as previously described [4] . The HPV-specific genomic profile was determined using the multivariate organization of combinatorial alterations (MOCA) algorithm [15] . Again the summary of the methods is provided in supplementary File, available at Annals of Oncology online.
ranking of gene-specific alterations
For HPV-positive and HPV-negative samples, we ranked genes by the percent of samples they were altered in, across the three cohorts. If a gene was not characterized in a particular cohort (denoted by NA), that cohort was removed from the average for the corresponding gene (e.g. SOX2 from the Chicago cohort).
estimation of alteration-per-sample counts for aggregate data
The FM cohort (N = 252) was consisted of 40 samples from Johns Hopkins University (FM-JHU) with a mutation profile per tumor and 212 samples with only aggregate data (FM-non-JHU). For the aggregate data, we knew the HPV tumor status associated with each alteration, but we were unable to determine which, if any, genes were altered more than once in a single sample. We estimated an alteration-per-sample count for each gene using the TCGA and the FM-JHU cohorts for which sample-specific genomic data were available; this estimation was done separately for HPV-positive and HPV-negative samples. For example there were 170 TP53 mutations observed in 160 HPV-negative samples in the aggregate data, indicating that original articles Annals of Oncology some samples had more than one TP53 mutation. Because TP53-mutated samples had an average of 1.19 TP53 mutations in the HPV-negative sample-specific data, we estimated that 143 of the 160 aggregate samples had at least one TP53 mutation (e.g. 170/1.19 = 143).
pathway assignments
We mapped the 236 altered genes from the three studies to the set of curated pathways available from the National Cancer Institute (NCI) Pathway Interaction Database (PID) [16] . NCI PID contains signaling interactions associated with major biomolecular and cellular processes. For genes that could be assigned to multiple pathways, we chose the pathways with the highest fraction of mapped genes from the 236 altered gene set. Additionally, knowledge of the functional classification of the major signaling molecules in the pathway was applied. As an example, the 'ErbB receptor signaling network' is a subpathway in the 'Epidermal growth factor/neuregulin signaling pathways', which are 'Growth factor signaling pathways'. Since this signaling is mediated by receptor tyrosine (RTK) signaling kinases, this and other pathways were grouped into RTK-GF pathway names.
determination of HPV-specific tumor suppressor and oncogene alteration fractions
Genes altered in the HPV-positive and HPV-negative HNSCC cohorts were categorized as 'tumor suppressor gene' (TSG), 'oncogene' (OG) or 'unknown' when no classification was available [17, 18] . 
HPV-positive HNSCC has a distinct HPV-specific genomic profile
We determined the differential genomic alterations in HPVpositive and HPV-negative HNSCC in the FM-JHU cohort with available sample-specific genomic data. First, we evaluated general distribution of the TSGs and OGs [17, 18] . In both HPV-positive and -negative HNSCCs, the mutations/copy number variations were more common in TSGs compared with OGs; however, HPV-positive tumors had a significantly higher frequency of having only OG alterations compared with HPVnegative tumors among the 236 evaluated genes (33% versus 6%, respectively; Figure 1A and B). The most common alteration by mutation and/or copy number variation in HPV-positive tumors was PIK3CA (30%) in the FM dataset, which is consistent with the TCGA and Chicago datasets (35% and 56%, respectively; Table 2 ). The PI3K pathway was also the most commonly altered pathway seen in HPV-positive tumors including alterations of PTEN (15%), AKT1 (5%), RICTOR (4%), mTOR (2%), AKT2 (2%), and PIK3R1 (2%) in addition to PIK3CA ( Figure 1A , Table 2,  and supplementary Table S2 , available at Annals of Oncology online). The most common alteration in HPV-negative tumors was TP53 (87%) in the FM dataset, which is again consistent with TCGA and Chicago cohorts (84% and 80%, respectively; Table 3 ). The most commonly altered pathways excluding TP53 are the cell cycle and PI3K pathways in HPV-negative tumors ( Figure 1B , Table 3 and supplementary Table S3 , available at Annals of Oncology online). This suggests that the selected cancer gene analysis using FFPE tumors obtained through routine clinical practice yield comparable assessment of genomic alterations to frozen tumors.
genomic profiles of HPV-positive SCC of oropharynx and nasal cavity/paranasal sinus We further evaluated a HPV-specific genomic profile using the MOCA algorithm in the TCGA cohort in order to assess the molecular similarities between HPV-positive oropharynx carcinoma and HPV-positive nasal cavity/paranasal sinus carcinoma. The top two most discriminating genes of HPV tumor status were TP53 and CDKN2A/B. The MOCA-derived composite marker combining TP53 mutation and CDKN2A/B loss discriminated HPV tumor status in TCGA cohort with 97% sensitivity and 91% specificity (P value = 4 × 10 −11 ). We also compared the genomic alterations in oropharynx and nasal cavity/ paranasal sinus carcinomas ( Figure 2 ). As seen in the oropharynx, absence of TP53 mutation and intact CDKN2A/B are also 
discussion
To realize the goal of personalized medicine, understanding the molecular underpinnings of HNSCC and the use of clinically applicable biomarker assays are key factors. Molecular characterization of HNSCC has been extensively published [8] [9] [10] [11] ; however, the WES or WGS data were generated in research settings using frozen tumors. While these datasets provide comprehensive evaluation of the molecular landscape, there are downsides to directly implementing the research methods to clinical application including; (i) FFPE tumors have fragmented and damage DNA such that robust DNA extraction and construction of sequencing library could be a challenge, (ii) diagnostic clinical samples are small tissue fragments, fine-needle aspirations or cell blocks which may be sufficient for histological testing, but frequently insufficient for comprehensive WES or WGS due to limited DNA yield, (iii) many clinical samples do not have high tumor cell contents in the tumor specimen; therefore, high sequence coverage across the entire tested regions is not always possible, and (iv) the analysis of WES or WGS data is labor intensive, time consuming, and costly, therefore, limiting the clinical applicability. Application of the targeted gene sequencing from FFPE tumors obtained from a routine clinical setting makes a practical sense and it is a first step toward clinical implementation.
In our study, we obtained aggregate genomic profile data from Foundation Medicine, Inc., for comparison with TCGA and Chicago datasets [10, 11] . Analysis of aggregate data included an estimated count of gene-specific alterations per patient based on the alteration frequency in the non-aggregate, patient-specific data (see Materials and Methods); this approach could be problematic if the distribution of gene-specific alterations varied significantly among the cohorts (e.g. a gene was, on average, altered ≥2 times per sample in the aggregate data). However, despite the heterogeneity of the FM cohort obtained from multiple tumor sites and varying medical practice settings with non-standardized tissue procurement methods, our data reveal remarkable similarities to the TCGA and Chicago cohorts supporting the feasibility of routine clinical testing to determine genomic alterations using FFPE tumors.
Corroborating a similar finding from the TCGA Network [10] , our multicohort study revealed that HPV-positive and HPV-negative HNSCC have distinct mutation profiles and most of the discriminating power is in the lack of TP53 mutations in HPV-positive HNSCCs and in the loss of CDKN2A/B in HPVnegative HNSCC. Indeed, loss of p53 function in HPV-positive HNSCCs through expression of the viral oncoprotein, E6, would negate selective pressure of gaining TP53 mutations. CDKN2A which encodes p16 protein is the most widely used surrogate marker of HPV-positive cancers and it is clearly established that up to 90% of HPV-negative HNSCC tumors lack p16 expression due to mutations, loss of heterozygosity, and/or promoter hypermethylation [10] . We found that PIK3CA was the most frequently mutated OG among HPV-positive patients in this multicohort study; a similar finding was recently reported by the TCGA Network [10] . In addition to confirming the PI3K pathway to be the most commonly altered pathway and potentially a very promising therapeutic target in HPV-positive HNSCC, we report the fibroblast growth factor (FGF) pathway may be a relevant therapeutic target in HPV-positive HNSCC. Novel agents targeting the FGF pathway are in active development [19] [20] [21] . With emerging data showing that there are phenotypical differences among the TP53 mutations associating with a high or low risk of poor survival and some mutants displaying oncogenic properties by a 'gainof-function' [22, 23] , relative lack of common TSG mutations in HPV-positive HNSCC may also suggest favorable response to targeted agents such as PI3K or FGFR inhibitors which warrant clinical evaluation. For HPV-negative patients with mutations predominantly in TSGs, innovative trial designs to evaluate synthetic lethality through combination regimens are necessary. Recent advances in understanding of excessive reliance on the G2-M checkpoint in tumors lacking p53 function have led to evaluation of Wee1 and Chk1 inhibitors, which suggest a significant potential for clinical development in HNSCC [24, 25] .
In addition to the oropharynx site within HNSCC, the presence of high-risk HPV is also found in nasal cavity/paranasal sinus carcinoma suggesting HPV as an important etiologic agent of carcinomas arising in the sinonasal tract. Unlike in HPV-positive oropharynx SCC, there is very limited molecular and clinical data for nasal cavity/paranasal sinus carcinoma, likely due to its rarity with annual incidence of only 0.5-1.0 patients per 100 000 [26, 27] . In the absence of the sinonasal tract cancer-specific data, clinicians have a tendency to extrapolate the data from the oropharynx SCC. Our genomic data suggest that further studies to evaluate the role of HPV and NFE2L2 (Nrf2) pathway in nasal cavity/paranasal sinus carcinoma are warranted.
Our study expands the current genomic data available surrounding HNSCC; however, further investigation is required to determine the clinical significance of these genomic alterations before use in routine clinical decision-making. Our data indicate that specimens obtained through routine clinical practice exhibit similar genomic profiles compared with those obtained in an academic setting, and demonstrate the feasibility of comprehensive genomic profiling using a CLIA-certified assay in a clinical setting. This is the first step toward development of future clinical trials using these genomic profiles as integral biomarkers. references
